Hirva Mamdani

17PUBLICATIONS
94CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 24, 2026
Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population.

|Feb 28, 2026
Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities.

Sonam Puri, Andrew Elliott, Abdul Rafeh Naqash

|Oct 23, 2025
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

Hirva Mamdani, Ryan D Gentzler, Lin Gu

|Jul 15, 2025
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081.

Greg Durm, Hirva Mamdani, Sandra Althouse

|Jan 03, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Jeffrey M Clarke, George R Simon, Hirva Mamdani

|Aug 22, 2024
Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy.

Elisabeth Heath, Gregory Dyson, Jennifer R Ribeiro

Pageof 3

Frequent Collaborators

6 joint publications

Natasha B Leighl

6 joint publications

Navneet Singh

4 joint publications

Narjust Florez

4 joint publications

Nofisat Ismaila